NO312068B1 - Pyrrolidinylmetylindolsalt - Google Patents
Pyrrolidinylmetylindolsalt Download PDFInfo
- Publication number
- NO312068B1 NO312068B1 NO19975210A NO975210A NO312068B1 NO 312068 B1 NO312068 B1 NO 312068B1 NO 19975210 A NO19975210 A NO 19975210A NO 975210 A NO975210 A NO 975210A NO 312068 B1 NO312068 B1 NO 312068B1
- Authority
- NO
- Norway
- Prior art keywords
- fumarate salt
- compound
- salt
- methylpyrrolidin
- ylmethyl
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 31
- BWQZTHPHLITOOZ-CQSZACIVSA-N n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C BWQZTHPHLITOOZ-CQSZACIVSA-N 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000012458 free base Substances 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000010525 oxidative degradation reaction Methods 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- TZQSNURHFSOKAI-WZGZYPNHSA-N (e)-but-2-enedioic acid;n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound OC(=O)\C=C\C(O)=O.C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C TZQSNURHFSOKAI-WZGZYPNHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9510223.2A GB9510223D0 (en) | 1995-05-20 | 1995-05-20 | Therapeutic agent |
| PCT/EP1996/001560 WO1996036632A1 (en) | 1995-05-20 | 1996-04-10 | Pyrrolidinyl methyl indole salt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975210D0 NO975210D0 (no) | 1997-11-13 |
| NO975210L NO975210L (no) | 1997-11-13 |
| NO312068B1 true NO312068B1 (no) | 2002-03-11 |
Family
ID=10774766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975210A NO312068B1 (no) | 1995-05-20 | 1997-11-13 | Pyrrolidinylmetylindolsalt |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US5994387A (zh) |
| EP (1) | EP0827503B1 (zh) |
| JP (1) | JP3233940B2 (zh) |
| KR (1) | KR100295255B1 (zh) |
| CN (1) | CN1063175C (zh) |
| AP (1) | AP738A (zh) |
| AR (1) | AR003949A1 (zh) |
| AT (1) | ATE194986T1 (zh) |
| AU (1) | AU701154B2 (zh) |
| BG (1) | BG63046B1 (zh) |
| BR (1) | BR9610858A (zh) |
| CA (1) | CA2219631C (zh) |
| CO (1) | CO5040221A1 (zh) |
| CZ (1) | CZ287939B6 (zh) |
| DE (1) | DE69609504T2 (zh) |
| DK (1) | DK0827503T3 (zh) |
| DZ (1) | DZ2034A1 (zh) |
| ES (1) | ES2148753T3 (zh) |
| GB (1) | GB9510223D0 (zh) |
| GR (1) | GR3034290T3 (zh) |
| HK (1) | HK1017884A1 (zh) |
| HR (1) | HRP960223B1 (zh) |
| HU (1) | HU217657B (zh) |
| IL (1) | IL118239A (zh) |
| IS (1) | IS1908B (zh) |
| LV (1) | LV11992B (zh) |
| MA (1) | MA23876A1 (zh) |
| MX (1) | MX9708966A (zh) |
| MY (1) | MY132066A (zh) |
| NO (1) | NO312068B1 (zh) |
| NZ (1) | NZ306448A (zh) |
| OA (1) | OA10747A (zh) |
| PL (1) | PL183142B1 (zh) |
| PT (1) | PT827503E (zh) |
| RU (1) | RU2161618C2 (zh) |
| SK (1) | SK281782B6 (zh) |
| TN (1) | TNSN96074A1 (zh) |
| TR (1) | TR199701397T1 (zh) |
| UA (1) | UA44320C2 (zh) |
| WO (1) | WO1996036632A1 (zh) |
| YU (1) | YU29496A (zh) |
| ZA (1) | ZA963938B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| WO2014012859A1 (en) * | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3906406C1 (zh) * | 1989-03-01 | 1990-10-25 | Goedecke Ag, 1000 Berlin, De | |
| RO111767B1 (ro) * | 1990-10-15 | 1997-01-30 | Pfizer | Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni |
| US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
-
1995
- 1995-05-20 GB GBGB9510223.2A patent/GB9510223D0/en active Pending
-
1996
- 1996-04-10 EP EP96912013A patent/EP0827503B1/en not_active Expired - Lifetime
- 1996-04-10 UA UA97126158A patent/UA44320C2/uk unknown
- 1996-04-10 BR BR9610858A patent/BR9610858A/pt not_active Application Discontinuation
- 1996-04-10 CZ CZ19973648A patent/CZ287939B6/cs not_active IP Right Cessation
- 1996-04-10 PT PT96912013T patent/PT827503E/pt unknown
- 1996-04-10 WO PCT/EP1996/001560 patent/WO1996036632A1/en active IP Right Grant
- 1996-04-10 ES ES96912013T patent/ES2148753T3/es not_active Expired - Lifetime
- 1996-04-10 NZ NZ306448A patent/NZ306448A/xx unknown
- 1996-04-10 TR TR97/01397T patent/TR199701397T1/xx unknown
- 1996-04-10 HU HU9801761A patent/HU217657B/hu not_active IP Right Cessation
- 1996-04-10 SK SK1541-97A patent/SK281782B6/sk unknown
- 1996-04-10 US US08/952,792 patent/US5994387A/en not_active Expired - Fee Related
- 1996-04-10 DE DE69609504T patent/DE69609504T2/de not_active Expired - Fee Related
- 1996-04-10 DK DK96912013T patent/DK0827503T3/da active
- 1996-04-10 RU RU97120998/04A patent/RU2161618C2/ru not_active IP Right Cessation
- 1996-04-10 JP JP53448896A patent/JP3233940B2/ja not_active Expired - Fee Related
- 1996-04-10 CA CA002219631A patent/CA2219631C/en not_active Expired - Fee Related
- 1996-04-10 KR KR1019970708280A patent/KR100295255B1/ko not_active IP Right Cessation
- 1996-04-10 AT AT96912013T patent/ATE194986T1/de not_active IP Right Cessation
- 1996-04-10 AU AU55005/96A patent/AU701154B2/en not_active Ceased
- 1996-04-10 CN CN96194043A patent/CN1063175C/zh not_active Expired - Fee Related
- 1996-04-10 MX MX9708966A patent/MX9708966A/es not_active IP Right Cessation
- 1996-04-10 PL PL96323143A patent/PL183142B1/pl unknown
- 1996-04-11 AP APAP/P/1996/000801A patent/AP738A/en active
- 1996-05-10 AR ARP960102519A patent/AR003949A1/es unknown
- 1996-05-13 IL IL11823996A patent/IL118239A/xx not_active IP Right Cessation
- 1996-05-16 HR HR960223A patent/HRP960223B1/xx not_active IP Right Cessation
- 1996-05-16 YU YU29496A patent/YU29496A/sh unknown
- 1996-05-17 ZA ZA9603938A patent/ZA963938B/xx unknown
- 1996-05-17 CO CO96025158A patent/CO5040221A1/es unknown
- 1996-05-17 TN TNTNSN96074A patent/TNSN96074A1/fr unknown
- 1996-05-17 MY MYPI96001888A patent/MY132066A/en unknown
- 1996-05-17 MA MA24243A patent/MA23876A1/fr unknown
- 1996-05-18 DZ DZ960077A patent/DZ2034A1/fr active
-
1997
- 1997-10-30 IS IS4605A patent/IS1908B/is unknown
- 1997-11-13 NO NO19975210A patent/NO312068B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102053A patent/BG63046B1/bg unknown
- 1997-11-20 OA OA70132A patent/OA10747A/en unknown
- 1997-12-11 LV LVP-97-256A patent/LV11992B/en unknown
-
1998
- 1998-10-20 HK HK98111337A patent/HK1017884A1/xx not_active IP Right Cessation
-
2000
- 2000-08-30 GR GR20000401977T patent/GR3034290T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1935892B1 (en) | Glycyrrhetinic acid-30-amide derivatives and the uses thereof | |
| NO326965B1 (no) | a-form eller β-form-krystall av acetanilid-derivat og farmasoytisk preparat | |
| IL100091A (en) | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| KR100667721B1 (ko) | 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴 | |
| GB2599950A (en) | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same | |
| WO2015158298A1 (zh) | 晶体、制备方法及其用途 | |
| US8202898B1 (en) | Pharmaceutical composition | |
| NO312068B1 (no) | Pyrrolidinylmetylindolsalt | |
| CA3051146A1 (en) | Crystal form of gft-505 and preparation method and use thereof | |
| WO2008085674A1 (en) | Pharmaceutical compositions comprising celecoxib co-crystals | |
| AU2016236659B9 (en) | AHU377 crystal form, preparation method and use thereof | |
| KR880001865B1 (ko) | 4-(1-이미다졸일메틸)신남산 하이드로클로라이드 모노하이드레이트의 제조방법 | |
| US20230382897A1 (en) | Crystalline form of lifitegrast, and pharmaceutical composition comprising the same | |
| JPH032183A (ja) | ビスベンジルイソキノリン誘導体 | |
| JPH0368578A (ja) | ビスベンジルイソキノリン誘導体 | |
| JPH0368557A (ja) | ビスべンジルイソキノリン誘導体 | |
| Karagiannidou | Setting Specifications for polymorphs in the Pharmaceutical Industry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |